| Literature DB >> 36098834 |
Yefei Zhang1, Xiang Lv1, Liming Chen2, Yan Liu3.
Abstract
Clusterin (CLU) is a highly evolutionary conserved glycoprotein with multiple isoform-specific functions and is widely distributed in different species. Accumulated evidence has shown the prominent role of CLU in regulating several essential physiological processes, including programmed cell death, metastasis, invasion, proliferation and cell growth via regulating diverse signaling pathways to mediate cancer progression in various cancers, such as prostate, breast, lung, liver, colon, bladder and pancreatic cancer. Several studies have revealed the potential benefit of inhibiting CLU in CLU inhibition-based targeted cancer therapies in vitro, in vivo or in human, suggesting CLU is a promising therapeutic target. This review discusses the multiple functions and mechanisms of CLU in regulating tumor progression of various cancers and summarizes the inhibitors of CLU used in CLU inhibition-based targeted cancer therapies.Entities:
Keywords: Cancer progression; Cancer therapy; Clusterin (CLU)
Year: 2022 PMID: 36098834 DOI: 10.1007/s10238-022-00885-2
Source DB: PubMed Journal: Clin Exp Med ISSN: 1591-8890 Impact factor: 5.057